Third time lucky for Lilly's solanezumab?
This article was originally published in Scrip
Alzheimer’s disease is one of the most challenging therapeutic targets to be pursued in pharmaceutical R&D. While research into this disease therapy has been somewhat successful in terms of developing symptomatic therapies, there has been a track record of failures for disease-modifying candidates – such as bapineuzumab (Johnson & Johnson/Pfizer). Moreover, there is still plenty of deliberation among the scientific community over the actual pathogenesis of Alzheimer’s disease and the different approaches to targeting its complex underlying mechanisms. But, with significant revenue potential waiting to be mined, Eli Lilly is firmly betting on the beta-amyloid approach, thus taking a great risk in the hope of achieving the high returns that it needs in order to offset one of the largest patent-cliffs within its Big Pharma peer-set, says Datamonitor Healthcare analyst Higia Vassoler.
You may also be interested in...
The European prostate cancer treatment space is characterized by economic austerity and strict reimbursement regulation. Nevertheless, Dendreon is preparing to launch Provenge in Europe in an attempt to counter the vaccine's disappointing US launch in April 2010. European health technology assessors have already blocked drugs which are more convenient and bear costs approximately one-third those of Provenge in the US. Adding those specific hurdles to the general economic environment for cancer drugs in Europe makes it likely that Dendreon will have to look for revenue growth elsewhere.